INmune Bio Harnessing the Innate Immune System to create Path breaking Therapeutics
INmune Bio (NASDAQ: INMB), a clinical-stage Company focussed on creating novel immunotherapies for the treatment of hematologic malignancies and solid tumors, announced the award of a grant of $500,000 by the ALS Association, an association not only providing care and assistance to those suffering from...
